ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

Bills Would Give FDA Authority to Approve Generic Biotech Drugs.

February 16, 2007

Also In This 12-page Issue: NCI To Cut Budgets For New Grants By 29 Percent. R01s To Be Funded At 11th Percentile.

February 3, 2006

Reimbursement Policy By Philadelphia Blue Cross Further Explained

April 21, 1989

In Brief: Little Doubt That DeVita, Frederickson Will Keep Their Jobs; New DCT Projects May Not Be Funded

March 6, 1981

Half of New NCI Funds in FY02 Spent on Grants

November 22, 2002

In Brief: Henney To Leave NCI For Kansas; Dan Longo Heads BRMP; DeVita To Receive Nervi Award

May 10, 1985